About

Ankeet Shah is an Assistant Professor of Urology at Duke University. He is based at Duke Medicine Circle, Duke Clinics, where he is involved in urology research and clinical practice. His role includes participation in the Urology Residency Program and the Duke Urologic Oncology Fellowship, contributing to education and training in the field of urology. Further details about his specific research focus, background, or key contributions are not provided in the available page text.

Research topics

• Medicine
• Internal medicine
• Surgery
• Gerontology
• Bioinformatics
• Oncology
• Urology
• Biology
• Intensive care medicine
• Environmental health

Selected publications

• Perioperative and oncologic outcomes of extirpative surgery for upper tract urothelial cancer in octogenarians

  Urologic Oncology Seminars and Original Investigations · 2026-03-02

  article
  PublisherDOI

• Topline results from BOND-003 cohort P: A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.

  Journal of Clinical Oncology · 2026-03-01

  article

  755 Background: Patients with High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer have limited treatment options. The US FDA approved treatments for BCG-UR patients with CIS, but additional bladder-sparing therapies are needed, especially for the BCG-UR papillary-only population. Cretostimogene is an oncolytic immunotherapy with dual mechanisms of action. It replicates in and lyses cancer cells with Rb-E2F pathway alterations. This releases tumor-specific antigens, initiating an anti-tumor immune response, further amplified by the GM-CSF transgene. The BOND-003 Cohort P study (NCT04452591) is a single-arm clinical trial assessing the efficacy and safety of intravesical cretostimogene in HR, papillary-only, BCG-UR NMIBC patients. Methods: Eligibility criteria include age ≥18 years, ECOG PS of 0-2, and histologically confirmed BCG-UR HG Ta/T1 papillary disease without CIS within 90 days of study enrollment as verified per central pathology review. Patients had no visible evidence of residual bladder cancer before treatment. Intravesical cretostimogene is instilled for six weekly doses during the induction phase, followed by three weekly maintenance cycles quarterly through Month 12, then every six months through Month 36. Re-induction is permitted at 3 months for patients with HG Ta or CIS. Primary disease assessments include serial cystoscopy, urine cytology, axial imaging, and mandatory biopsy directed at prior tumor locations at Month 12, with centralized review of pathologic samples. Endpoints include HG-RFS, HG-EFS, PFS, and safety. The study has completed enrollment. Results: A total of 56 patients who received treatment with cretostimogene are evaluated based on data from September 1, 2025 cut off. At baseline, 76.7% of patients are 65 years or older, 21.4% are female, 64.3% have HG Ta, and 35.7% have HG T1 papillary NMIBC. Kaplan-Meier estimates of HG-RFS at 6- and 9-months are 84.6% (95% CI 73.1 - 96.1%) and 80.4% (95% CI 66.8-94.0%), respectively. No patients have undergone a radical cystectomy. One patient progressed to metastatic disease despite a clinical complete response in the bladder. Cretostimogene demonstrates a favorable safety profile, with most adverse events localized to low grade bladder symptoms. There are no serious treatment-related adverse events and no discontinuations related to cretostimogene. To date, no patients have required a dose delay or missed a dose due to a related adverse event. There have been no deaths related to study treatment. Further, updated data will be presented. Conclusions: These results demonstrate consistent efficacy and a well-tolerated safety profile. Mature data with longer term follow-up will build upon these promising findings and will inform future treatment approaches with cretostimogene. Clinical trial information: NCT04452591 .

  PublisherDOI

• Does Cardiopulmonary Bypass Affect Outcomes in Nephrectomy with Level III/IV Caval Thrombectomy for Renal Cell Carcinoma?

  Current Oncology · 2025-11-29

  articleOpen access

  Radical nephrectomy with inferior vena cava (IVC) thrombectomy is a technically complex procedure. Cardiopulmonary bypass (CPB) is frequently employed for managing high-level thrombi, yet its impact on surgical outcomes remains uncertain. This study evaluated the outcomes of radical nephrectomy with level III/IV thrombectomy with or without CPB. We retrospectively reviewed records of patients with renal cell carcinoma and level III/IV (Mayo classification) thrombi who underwent open radical nephrectomy and IVC thrombectomy at our center between January 2000 and December 2023. Perioperative and survival outcomes were compared between patients in the CPB and non-CPB groups. Multivariable regression identified clinical factors associated with all-grade complications and survival. Primary and secondary outcomes were 90-day complications and overall survival. Fifty-seven patients were included: 30 (53%) in the CPB group and 27 (47%) in the non-CPB group. Within 90 days, overall complication and mortality rates were 49% and 10.5%; no statistically significant differences were observed between groups. In multivariable models, CPB was not independently associated with 90-day complications (odds ratio [OR] 0.55, 95% CI 0.13–2.12, p = 0.4) or overall survival (hazard ratio [HR] 1.34, 95% CI 0.65–2.78, p = 0.41). In our cohort, we did not find CPB use to independently influence perioperative complications or survival outcomes in radical nephrectomy with level III/IV IVC thrombectomy.

  PublisherOA PDFDOI

• IP07-30 ACUTE KIDNEY INJURY FOLLOWING RADICAL NEPHRECTOMY AND INFERIOR VENA CAVA THROMBECTOMY: A TERTIARY REFERRAL CENTER EXPERIENCE

  The Journal of Urology · 2025-04-08

  article
  PublisherDOI

• NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025

  Journal of the National Comprehensive Cancer Network · 2025-04-01 · 19 citations

  articleOpen access

  The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.

  PublisherOA PDFDOI

• MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER

  The Journal of Urology · 2025-04-08

  articleSenior author
  PublisherDOI

• DISPARITIES IN UROLOGIC ONCOLOGY: ANALYSIS OF THE SOCIETY OF UROLOGIC ONCOLOGY FELLOWSHIP MATCH STATISTICS 2019–2024

  Urologic Oncology Seminars and Original Investigations · 2025-02-27

  article
  PublisherDOI

• Letter: Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit

  The Journal of Urology · 2025-05-13

  letter
  PublisherDOI

• Hyperthermia, bladder pressure, and intravesical drug delivery.

  Journal of Clinical Oncology · 2021-02-20

  article

  469 Background: Little is known about the pharmacokinetics of intravesical chemotherapies. Various parameters can be altered including temperature, dwell time, drug concentration, and bladder pressure. Here, we hypothesize that increasing bladder pressure during instillation will improve drug delivery. Methods: An ex-vivo porcine model was developed to evaluate determinants of drug penetration into the bladder wall. Porcine bladders were suspended in isotonic saline at 37°C with a three-way Foley catheter in the bladder. Temperature probes were positioned in the extravesical bathing solution, bladder lumen, and sutured to the detrusor to ensure maintenance of desired temperatures. 2g gemcitabine in 100mL normal saline was heated to 43°C and circulated through the bladder using the Combat Bladder Recirculation System. Bladder pressures were monitored throughout each trial. After 60 minutes of dwell time, rapid dissection was performed to obtain full-thickness bladder samples from the bladder dome, posterior wall, trigone, and left and right lateral walls. Tissue was homogenized and liquid chromatography with tandem mass spectrometry (LC/MS/MS) was performed to measure gemcitabine concentration within the bladder wall. Linear regression and Pearson correlation were performed to determine the association between mean bladder pressure during instillation and drug concentration within the bladder wall. Multiple linear regression was conducted to control for bladder location and thickness. Results: Gemcitabine concentration within the bladder wall was measured 25 times across five trials. Mean gemcitabine concentration within bladder wall was 3.68 mg/g (sd 1.35). Pressure ranged from 149.8 mmHg to 277.7 mmHg (mean 194.8, sd 22.0). On univariate analysis, higher pressure was associated with increased gemcitabine concentration within the bladder wall (correlation = 0.49, p = 0.013). This result persisted after adjusting for bladder location (ß = 0.49, p = 0.006) and thickness (ß = 0.70, p = 0.03). Unstandardized regression coefficient in each of the models was 0.099 (mmHg x g)/mg, demonstrating that for each pressure increase of 10mmHg there was an associated increase in gemcitabine concentration of approximately 1 mg/g (Table). Conclusions: Data suggest that bladder pressure dramatically improves the extent of gemcitabine penetration into the bladder wall. Future research is needed to evaluate the therapeutic effect of increased gemcitabine delivery to target tissue in patients with bladder cancer. [Table: see text]

  PublisherDOI

• Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non–muscle invasive bladder cancer during BCG shortage

  Urologic Oncology Seminars and Original Investigations · 2021 · 12 citations

  • Medicine
  • Urology
  • Surgery
  PublisherDOI

Frequent coauthors

• Siamak Daneshmand

  University of Southern California

  20 shared

• Hooman Djaladat

  15 shared

• Anne Schuckman

  University of Southern California

  15 shared

• Brant A. Inman

  Western University

  13 shared

• D Grimberg

  Duke Medical Center

  13 shared

• Gus Miranda

  Keck Hospital of USC

  11 shared

• Saum Ghodoussipour

  Rutgers Cancer Institute of New Jersey

  10 shared

• Shane M. Pearce

  8 shared